These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18572503)

  • 1. [Phage lytic enzymes--new hope in battle against bacterial infections].
    Niczyporuk JS; Bartoszcze M
    Przegl Epidemiol; 2007; 61(4):713-21. PubMed ID: 18572503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriophage lytic enzymes: novel anti-infectives.
    Fischetti VA
    Trends Microbiol; 2005 Oct; 13(10):491-6. PubMed ID: 16125935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taking aim on bacterial pathogens: from phage therapy to enzybiotics.
    Hermoso JA; García JL; García P
    Curr Opin Microbiol; 2007 Oct; 10(5):461-72. PubMed ID: 17904412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophages, phage endolysins and antimicrobial peptides - the possibilities for their common use to combat infections and in the design of new drugs.
    Mirski T; Lidia M; Nakonieczna A; Gryko R
    Ann Agric Environ Med; 2019 Jun; 26(2):203-209. PubMed ID: 31232046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.
    Oliveira H; São-José C; Azeredo J
    Viruses; 2018 May; 10(6):. PubMed ID: 29844287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications.
    Donovan DM
    Recent Pat Biotechnol; 2007; 1(2):113-22. PubMed ID: 19075835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endolysins as antimicrobials.
    Nelson DC; Schmelcher M; Rodriguez-Rubio L; Klumpp J; Pritchard DG; Dong S; Donovan DM
    Adv Virus Res; 2012; 83():299-365. PubMed ID: 22748813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bacteriophage lysins: progress and perspective--a review].
    Wang Y; Lu C
    Wei Sheng Wu Xue Bao; 2009 Oct; 49(10):1277-81. PubMed ID: 20069871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriophage endolysins as a novel class of antibacterial agents.
    Borysowski J; Weber-Dabrowska B; Górski A
    Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phage therapy: a reappraisal of bacteriophages as antibiotics.
    Inal JM
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):237-44. PubMed ID: 12956433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phage Lytic Enzymes.
    Briers Y
    Viruses; 2019 Jan; 11(2):. PubMed ID: 30699900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections.
    Gondil VS; Harjai K; Chhibber S
    Int J Antimicrob Agents; 2020 Feb; 55(2):105844. PubMed ID: 31715257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LambdaSa2 prophage endolysin requires Cpl-7-binding domains and amidase-5 domain for antimicrobial lysis of streptococci.
    Donovan DM; Foster-Frey J
    FEMS Microbiol Lett; 2008 Oct; 287(1):22-33. PubMed ID: 18673393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics.
    Rodríguez-Rubio L; Martínez B; Donovan DM; Rodríguez A; García P
    Crit Rev Microbiol; 2013 Nov; 39(4):427-34. PubMed ID: 22991936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model.
    Jado I; López R; García E; Fenoll A; Casal J; García P;
    J Antimicrob Chemother; 2003 Dec; 52(6):967-73. PubMed ID: 14613958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding domains of Bacillus anthracis phage endolysins recognize cell culture age-related features on the bacterial surface.
    Paskaleva EE; Mundra RV; Mehta KK; Pangule RC; Wu X; Glatfelter WS; Chen Z; Dordick JS; Kane RS
    Biotechnol Prog; 2015; 31(6):1487-93. PubMed ID: 26399565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of the antibacterial properties of the recombinant phage endolysins AP50-31 and LysB4 as potent bactericidal agents against Bacillus anthracis.
    Park S; Jun SY; Kim CH; Jung GM; Son JS; Jeong ST; Yoon SJ; Lee SY; Kang SH
    Sci Rep; 2018 Jan; 8(1):18. PubMed ID: 29311588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysins as a powerful alternative to combat Bacillus anthracis.
    Nakonieczna A; Abramowicz K; Kwiatek M; Kowalczyk E
    Appl Microbiol Biotechnol; 2024 Jun; 108(1):366. PubMed ID: 38850320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriophage endolysins--current state of research and applications.
    Loessner MJ
    Curr Opin Microbiol; 2005 Aug; 8(4):480-7. PubMed ID: 15979390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriophage endolysins as novel antimicrobials.
    Schmelcher M; Donovan DM; Loessner MJ
    Future Microbiol; 2012 Oct; 7(10):1147-71. PubMed ID: 23030422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.